Press release
Leiomyosarcoma Clinical Trials 2024: FDA Approval, Medications, Treatment Drugs, MOA , ROA, and Companies by DelveInsight | Merck, Advenchen Laboratories, Trillium Therapeutics, PTC Therapeutics, PharmaMar, Philogen, EMD Serono, Incyte Corporation, Clovis
Leiomyosarcoma Clinical Trials
Discover the latest drugs and treatment options in the Leiomyosarcoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Leiomyosarcoma Pipeline Outlook https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Leiomyosarcoma Pipeline Report
• June 2024:- PharmaMar- Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Patients With Metastatic Leiomyosarcoma. The primary objective of this phase IIb/III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
• June 2024:- PTC Therapeutics- A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma. This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or metastatic, relapsed or refractory LMS who have received at least 1 prior line of systemic therapy.
• DelveInsight's Leiomyosarcoma Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading Leiomyosarcoma Companies such as Merck, Advenchen Laboratories, Trillium Therapeutics, PTC Therapeutics, PharmaMar, Philogen, EMD Serono, Incyte Corporation, Clovis Oncology, Inc., and others.
• Promising Leiomyosarcoma Therapies such as Lurbinectedin, Doxorubicin, Unesbulin, Dacarbazine, Rucaparib, Nivolumab, Dinutuximab Beta, Zoledronic acid, Interleukin-2, and others.
Stay ahead with the most recent pipeline outlook for Leiomyosarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Leiomyosarcoma Approved Drugs- https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Leiomyosarcoma Emerging Drugs Profile
• ADI PEG20: Polaris Group
ADI-PEG 20 is a first-in-class therapeutic approach to deplete arginine and starve cancer cells. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, some cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient's normal cells unharmed. Currently, it is in Phase III stage of clinical trial evaluation to treat Leiomyosarcoma.
• OR2805: OncoResponse
OR2805 is a fully human monoclonal antibody that targets CD163, an immune-suppressive receptor highly expressed on tumor-associated macrophages (TAMs). It was discovered using B cells derived from an elite responder to checkpoint inhibitor (CPI) therapy and is designed to reverse the immunosuppressive effect of TAMs, enhancing anti-tumor T-cell responses. In preclinical studies, OR2805 showed significant anti-tumor activity in lung cancer xenograft models in humanized mice and relieved the suppressive effect of M2c macrophages in coculture assays. OR2805 is currently being evaluated in a Phase I/II clinical trial to assess its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with Leiomyosarcoma. The trial includes a dose-escalation phase, expansion cohorts, and a biology cohort to evaluate potential biomarkers. OR2805 has the potential to improve anti-tumor T-cell responses by reversing the immunosuppressive effect of TAMs, making it a promising therapeutic strategy for treating advanced cancers.
Explore groundbreaking therapies and clinical trials in the Leiomyosarcoma Pipeline. Access DelveInsight's detailed report now! @ Leiomyosarcoma Treatment Drugs- https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Leiomyosarcoma Companies
Merck, Advenchen Laboratories, Trillium Therapeutics, PTC Therapeutics, PharmaMar, Philogen, EMD Serono, Incyte Corporation, Clovis Oncology, Inc., and others.
Leiomyosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
Leiomyosarcoma Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Unveil the future of Leiomyosarcoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Leiomyosarcoma Market Drivers and Barriers- https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Leiomyosarcoma Pipeline Report
• Coverage- Global
• Leiomyosarcoma Companies- Merck, Advenchen Laboratories, Trillium Therapeutics, PTC Therapeutics, PharmaMar, Philogen, EMD Serono, Incyte Corporation, Clovis Oncology, Inc., and others.
• Leiomyosarcoma Therapies- Lurbinectedin, Doxorubicin, Unesbulin, Dacarbazine, Rucaparib, Nivolumab, Dinutuximab Beta, Zoledronic acid, Interleukin-2, and others.
• Leiomyosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• LeiomyosarcomaTherapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Leiomyosarcoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Leiomyosarcoma Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Leiomyosarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Leiomyosarcoma - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Leiomyosarcoma Collaboration Deals
9. Late Stage Products (Phase III)
10. AL-3818: Advenchen Laboratories
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. OR2805: OncoResponse
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Leiomyosarcoma Key Companies
20. Leiomyosarcoma Key Products
21. Leiomyosarcoma- Unmet Needs
22. Leiomyosarcoma- Market Drivers and Barriers
23. Leiomyosarcoma- Future Perspectives and Conclusion
24. Leiomyosarcoma Analyst Views
25. Leiomyosarcoma Key Companies
26. Appendix
Trending Reports:
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Balloon Catheters Market Market: https://www.delveinsight.com/report-store/balloon-catheters-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Biliary Stents Market: https://www.delveinsight.com/report-store/biliary-stents-market
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Gastroenteropancreatic Neuroendocrine Tumors Market: https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Precocious Puberty Market: https://www.delveinsight.com/report-store/precocious-puberty-market
• Acne Vulgaris Market: https://www.delveinsight.com/report-store/acne-vulgaris-av-market
• Acquired Immunodeficiency Syndrome Market: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-market
• Acute Pharyngitis Market: https://www.delveinsight.com/report-store/acute-pharyngitis-market
• Adenoid Cystic Carcinoma Market: https://www.delveinsight.com/report-store/adenoid-cystic-carcinoma-acc-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Autosomal Recessive Congenital Ichthyosis Market Size: https://www.delveinsight.com/report-store/congenital-ichthyosis-market
• Bacteremia Market: https://www.delveinsight.com/report-store/bacteremia-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/intracranial-stents-market
• Burn Market: https://www.delveinsight.com/report-store/burn-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiac Restoration Systems Market: https://www.delveinsight.com/report-store/cardiac-restoration-systems-market
• Chemotherapy Induced Febrile Neutropenia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
• Chronic Idiopathic Urticaria Market: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market
• Chronic Plaque Psoriasis Market: https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
• Colorectal Cancer Crc Market: https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-market
• Contraceptive Devices Market: https://www.delveinsight.com/report-store/contraceptive-devices-market
• Diabetic Neuropathy Market: https://www.delveinsight.com/report-store/diabetic-peripheral-neuropathy-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Giant Papillary Conjunctivitis Market: https://www.delveinsight.com/report-store/giant-papillary-conjunctivitis-market
• Neuroprosthetics Market: https://www.delveinsight.com/report-store/neuroprosthetics-market-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Postmenopausal Vaginal Atrophy Market: https://www.delveinsight.com/infographics/atrophic-vaginitis-market
• Progressive Familial Intrahepatic Cholestasis Market: https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market
• Vestibular Schwannoma Market: https://www.delveinsight.com/report-store/vestibular-schwannoma-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leiomyosarcoma Clinical Trials 2024: FDA Approval, Medications, Treatment Drugs, MOA , ROA, and Companies by DelveInsight | Merck, Advenchen Laboratories, Trillium Therapeutics, PTC Therapeutics, PharmaMar, Philogen, EMD Serono, Incyte Corporation, Clovis here
News-ID: 3690556 • Views: …
More Releases from DelveInsight Business Research
Peripheral T-Cell Lymphoma (PTCL) Market Analysis 2034 - Competitive Landscape, …
The Peripheral T-Cell Lymphoma (PTCL) Market across the 7MM was valued at approximately USD 680 million in 2020, and it is projected to experience steady growth by 2034.
Peripheral T-Cell Lymphoma (PTCL) Market Overview
As of 2023, the United States held the largest share of the PTCL therapeutics market within the 7MM, reaching a valuation of around USD 500 million, followed by Japan. Newly diagnosed patients are generally managed with anthracycline-based chemotherapy…
Nontuberculous Mycobacterial Infection Market Analysis 2034 - Competitive Landsc …
In 2023, the Nontuberculous Mycobacterial (NTM) Infections Market in the United States was valued at around USD 360 million, and it is projected to grow throughout the 2024-2034 forecast period.
Nontuberculous Mycobacterial Market Overview
The NTM infections market is anticipated to expand consistently between 2024 and 2034, fueled by advancements in diagnostics, the introduction of novel therapies, and growing disease awareness. The aging population, which is more susceptible to NTM infections, continues…
Lupus Nephritis Market Analysis 2034 - Competitive Landscape, Clinical Trials, M …
The Lupus Nephritis (LN) market was valued at approximately USD 1.8 billion in 2024 and is projected to expand steadily from 2025 to 2034, driven by the introduction of emerging therapies across the seven major markets (7MM).
Lupus Nephritis Market Summary
In Japan, the Lupus Nephritis market size was around USD 49 million in 2024, and it is anticipated to grow throughout the forecast period (2025-2034). Lupus Nephritis, a serious complication of…
Sjogren's Syndrome Market Outlook 2034 - Clinical Trials, Market Size, Medicatio …
Prominent Sjogren's syndrome companies include Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and several others.
Sjogren's Syndrome Market Summary
In 2023, the Sjogren's syndrome market size across the seven major markets (7MM) was valued at approximately USD 1.9 billion and is expected to witness steady growth through 2034.
Sjogren's syndrome is an autoimmune disease that primarily disrupts the salivary…
More Releases for Leiomyosarcoma
Uterine Leiomyosarcoma Market is expected to reach USD 1.2 billion by 2034
Uterine leiomyosarcoma (uLMS) is a rare but highly aggressive subtype of soft tissue sarcoma that originates in the smooth muscle layer of the uterus. Unlike benign fibroids, uLMS is often diagnosed at advanced stages and is associated with poor prognosis, high recurrence rates, and limited treatment options. Representing less than 1% of all uterine cancers, it nevertheless accounts for a disproportionate share of mortality in gynecologic oncology.
Download Full PDF Sample…
Leiomyosarcoma Drug Market Estimated to Experience a Hike in Growth by 2033
The Leiomyosarcoma Drug Market was valued at USD 0.72 billion in 2023, and it is projected to reach USD 1.55 billion by 2033, growing at a CAGR of 8.0% from 2024 to 2033.
Leiomyosarcoma Drug Market Overview
The Leiomyosarcoma Drug Market is expanding due to the increasing prevalence of soft tissue sarcomas and advancements in oncology therapeutics. Leiomyosarcoma, a rare but aggressive cancer, has driven demand for more effective and targeted treatments.…
Leiomyosarcoma Treatment Market Thrives with Strong Growth Prospects During 2024 …
A new report published by CoherentMI, titled "Leiomyosarcoma Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Leiomyosarcoma Treatment market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The leiomyosarcoma treatment market is estimated to be valued at USD 1.3 billion in 2024 and is expected to reach USD 2.4…
Leiomyosarcoma Clinical Trials, Treatment Drugs, Emerging Drugs, and Companies 2 …
DelveInsight's, "Leiomyosarcoma Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Leiomyosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Leiomyosarcoma Pipeline. Dive…
Leiomyosarcoma Treatment Market is expected to reach USD 834.12 million by 2030
Global leiomyosarcoma treatment market has experienced significant growth due to the increased prevalence of soft tissue sarcomas is one of the driving factors for the global leiomyosarcoma treatment market. For instance, in the U.S., total new cases diagnosed for soft tissue sarcomas are 13,460 and 5,350 people which are expected to die from this type of cancer. Increase in women population having fibroids may have the chances to develop LMS…
Leiomyosarcoma Pipeline | Clinical Trials, Key Companies- Merck, PTC Therapeutic …
DelveInsight's, "Leiomyosarcoma - Pipeline Insight, 2023," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Leiomyosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download Sample Report to learn more @https://www.delveinsight.com/sample-request/leiomyosarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Leiomyosarcoma Overview
Leiomyosarcoma is a type of…
